Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective, single center study for effect of the neutrophil-to-lymphocyte ratio on the survival of patients with unresectable advanced or metastatic gastric or gastroesophageal adenocarcinoma treated with nivolumab

Next Previous
Trial Profile

Retrospective, single center study for effect of the neutrophil-to-lymphocyte ratio on the survival of patients with unresectable advanced or metastatic gastric or gastroesophageal adenocarcinoma treated with nivolumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Mar 2022 Results published in the Anticancer Research
  • 27 Apr 2020 New trial record
  • 12 Apr 2020 Results (n=89) published in the Targeted Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top